May 16, 2021

Premium Newspaper

The Premium News Provider

Bajaj Healthcare releases generic favipiravir tablets to treat COVID-19

On Tuesday, the pharmaceutical company announced the release of the anti-viral tablets Favipiravir under the brand name ‘Favijaj’ used to treat mild to moderate infections of COVID-19 in the country.

Bajaj Healthcare said in a BSE file that the company has received approval from the Medicines Regulatory Authority of India DCGI to manufacture and market the tablets.

“We hope that the availability of an effective treatment such as Favijaj will significantly reduce pressure and provide much-needed treatment options for patients,” said Dr. Anil Jain Bajaj Healthcare Joint MD.

Bajaj Healthcare said that the company has succeeded in developing Active Pharmaceutical Ingredient (API) and formulating faviravir through its in-house R&D team.

Shares of Bajaj Healthcare closed at Rs 583.05 per sheet on BSE, up sharply 10.85 per cent from its previous close.